# CRISPR THERAPEUTICS AG (CRSP) FY2026 YTD Q2 P&L / Income Statement

- Company: CRISPR THERAPEUTICS AG (CRSP)
- Period: 2026-01-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001193125-26-330672
- Page: https://plicit.ai/financials/crsp/fy2026-ytd-q2-income-statement
- Chart image: https://plicit.ai/charts/crsp-fy2026-ytd-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenue**: 11,639,000 US dollars
- **Total operating expenses**: 259,156,000 US dollars
- **Loss from operations**: negative 247,517,000 US dollars
- **Total other income, net**: 35,231,000 US dollars
- **Net loss before income taxes**: negative 212,286,000 US dollars
- **Provision for income taxes**: 1,799,000 US dollars
- **Net loss**: negative 214,085,000 US dollars
- **Collaboration Revenue**: 11,000,000 US dollars
- **Grant Revenue**: 639,000 US dollars
- **Total operating expenses**: 259,156,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.